Drug profile · INN
elranatamab
ELREXFIO
elranatamab (ELREXFIO) is a t cell surface glycoprotein cd3 binding agent. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — elranatamab
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 8
- Data quality
- 0.84
Quick answer
elranatamab (ELREXFIO) is a t cell surface glycoprotein cd3 binding agent. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
T cell surface glycoprotein CD3 binding agent
Primary target: T cell surface glycoprotein CD3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Bispecific Antibody Approvals in EU: Teclistamab & Elranatamab Review
This article reviews the recent EU approvals of teclistamab and elranatamab, highlighting their significance in treating multiple myeloma.
FDA Approval Elranatamab: Efficacy, Safety & Market Impact in RRMM
Elranatamab has gained FDA approval for relapsed/refractory multiple myeloma, showcasing promising efficacy and safety, and is set to impact the market significantly.
Pfizer's ELREXFIO Shows Significant Progression-Free Survival Improvement in Multiple Myeloma Phase 3 Trial
Pfizer's ELREXFIO meets primary endpoint in MagnetisMM-5 Phase 3 trial, showing statistically significant progression-free survival improvement for relapsed multiple myeloma patients.
PRAC Safety Signal Assessment: Insights on Bispecific Antibodies in Hematologic Malignancies
This article delves into PRAC's assessment of safety signals related to bispecific antibodies, focusing on their efficacy and safety in treating hematologic malignancies.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is elranatamab?
elranatamab (ELREXFIO) is a t cell surface glycoprotein cd3 binding agent. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for elranatamab?
ELREXFIO is a marketed brand name for elranatamab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of elranatamab?
elranatamab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.